ZALTRAP Special Drug Use Surveillance (Unresectable advanced and/or recurrent colorectal cancer)

ZALTRAP Special Drug Use Surveillance (Unresectable advanced and/or recurrent colorectal cancer) - ZALTRAP Special Drug Use Surveillance (Unresectable advanced and/or recurrent colorectal cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028897

Enrollment

200

Registered

2017-11-01

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with unresectable advanced and/or recurrent colorectal cancer -Patients newly treated by ZALTRAP

Exclusion criteria

Exclusion criteria: Patients concurrently participating in any interventional clinical studies

Design outcomes

Primary

Measure	Time frame
Safety: Incidence rate of adverse drug reaction Effectiveness: Tumor assessment	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance -

Sanofi K.K. Post-marketing regulatory study, Medical Affairs

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results